Cas:92003-62-8 4-tert-butylcalix(6)arene-hexaacetic acid hexaethyl ester manufacturer & supplier

Chemical Name:4-tert-butylcalix(6)arene-hexaacetic acid hexaethyl ester

CAS.NO:92003-62-8

Synonyms:Cesium ionophore II;MFCD01863235

Molecular Formula:C₉₀H₁₂₀O₁₈

Molecular Weight:1489.90000

HS Code:29329900

Physical and Chemical Properties:

Melting point:257-263ºC

Boiling point:1167.6ºC at 760 mmHg

Density:1.095g/cm3

Index of Refraction:1.529

PSA:213.18000

Exact Mass:1488.85000

LogP:16.98120

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:NONH for all modes of transpor

Packing Group:

Contact us for information like Cesium ionophore II chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,MFCD01863235 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,MFCD01863235 Use and application,Cesium ionophore II technical grade,usp/ep/jp grade.

Related News: Britons being brought from Wuhan to the UK are being placed in quarantine at Arrowe Park Hospital in the Wirral, northwest England, Raab said. 4-tert-butylcalix(6)arene-hexaacetic acid hexaethyl ester manufacturer Delta moved the date up after the US State Department warned that people should not travel to China due to concerns about the spread of coronavirus, which was first discovered in Wuhan, Hubei province, in December. 4-tert-butylcalix(6)arene-hexaacetic acid hexaethyl ester supplier Beta Bionics is committed to obtaining regulatory approval and commercializing all three iLet configurations. 4-tert-butylcalix(6)arene-hexaacetic acid hexaethyl ester vendor Delta moved the date up after the US State Department warned that people should not travel to China due to concerns about the spread of coronavirus, which was first discovered in Wuhan, Hubei province, in December. 4-tert-butylcalix(6)arene-hexaacetic acid hexaethyl ester factory In March 2021, Reuters reported that a former Lilly human resources officer, Amrit Mula, had identified internally some of the same violations later documented by the FDA. Mula was forced out of the company in early 2019 after Lilly executives sought to downplay her findings, according to a letter demanding compensation for damages that her attorneys sent to the company.